AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11399694 — intervention group
Group type: EXPERIMENTAL
Intervention: Active group (n = 36) participated in a 6-week program of education (2 h weekly) and exercise (1 h weekly)
Number of subjects: 65
Study 11399694 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 29) reviewed routinely as medical outpatients
Number of subjects: 65
Study 11399694 — intervention group
Group type: COMPARATOR
Intervention: Active group vs Control group at 12 weeks
Number of subjects: 65
Study 11399694 — intervention group
Group type: COMPARATOR
Intervention: Active group vs Control group at 24 weeks
Number of subjects: 65
Study 9295454 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-the-shelf orthopedic footwear
Number of subjects: 30
Study 9295454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 8369010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferro‐Folsan (100 mg of ferrous‐II‐sulfate and 0.85 mg of folic acid)
Number of subjects: 14
Study 3737298 — intervention group
Group type: COMPARATOR
Intervention: Formula samples given at discharge from the hospital
Number of subjects: 166
Study 3737298 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal factors (age, education, nonsmoking, previous breast-feeding, planned pregnancy, initiation of breast-feeding in the first 16 hours, minimization of formula supplementation)
Number of subjects: 166
Study 3737298 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breast-feeding (supplementing more than one bottle of formula per day)
Number of subjects: 166
Study 3737298 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nursing (seven or more times per day) despite formula supplementation
Number of subjects: 166
Study 28277441 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with implantation of an intraocular lens
Number of subjects: 21
Study 29771077 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol melitracen (1 tablet/day) for 3 months
Number of subjects: 163
Study 29771077 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 163
Study 26503843 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 60
Study 24491199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness treatment group (MTG)
Number of subjects: 91
Study 24491199 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 91
Study 22144668 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogen sulfate (CHS) 75 mg/d
Number of subjects: 86
Study 22144668 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel besylate (CB) 75 mg/d
Number of subjects: 86
Study 20666753 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser with water cooling
Number of subjects: 28
Study 20666753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with water cooling
Number of subjects: 28
Study 20666753 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser without water cooling
Number of subjects: 28
Study 20666753 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser without water cooling
Number of subjects: 28
Study 17989536 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom immunotherapy
Number of subjects: 0
Study 17989536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid protocols for venom immunotherapy
Number of subjects: 0
Study 17989536 — intervention group
Group type: EXPERIMENTAL
Intervention: Venom immunotherapy in patients with mast cell diseases
Number of subjects: 0
Study 17989536 — intervention group
Group type: EXPERIMENTAL
Intervention: New strategies for venom immunotherapy (genetic engineering)
Number of subjects: 0
Study 15370157 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine immunoassay test strips (ITS)
Number of subjects: 236
Study 15370157 — intervention group
Group type: COMPARATOR
Intervention: Gas chromatography/mass spectrometry (GC/MS)
Number of subjects: 236
Study 11259736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g) in pregnant women
Number of subjects: 30
Study 11259736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g) in non-pregnant women
Number of subjects: 30
Study 11259736 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose loading (75 g)
Number of subjects: 30
Study 9676408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 60
Study 9676408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 60
Study 9676408 — intervention group
Group type: COMPARATOR
Intervention: Control group (TURP)
Number of subjects: 60
Study 9676408 — intervention group
Group type: COMPARATOR
Intervention: Control group (TUVP)
Number of subjects: 60
Study 7991315 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstract paintings
Number of subjects: 51
Study 7991315 — intervention group
Group type: EXPERIMENTAL
Intervention: Realistic paintings
Number of subjects: 51
Study 3059399 — intervention group
Group type: EXPERIMENTAL
Intervention: iopamidol (IOP, 20 cases)
Number of subjects: 50
Study 3059399 — intervention group
Group type: EXPERIMENTAL
Intervention: 76% Na‐meglumine diatrizoate (76% UG, 20 cases)
Number of subjects: 50
Study 3059399 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% Na‐meglumine diatrizoate (38% UG, 10 cases)
Number of subjects: 50
Study 31762210 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy questionnaires (NQ) and nerve conduction studies (NCS) in patients with RD
Number of subjects: 100
Study 31762210 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy questionnaires (NQ)
Number of subjects: 100
Study 31762210 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 100
Study 30061289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 8, 12, or 16 weeks
Number of subjects: 2200
Study 30061289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir for 12 weeks
Number of subjects: 2200
Study 30061289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir regimen
Number of subjects: 2200
Study 30061289 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Number of subjects: 2200
Study 28751099 — intervention group
Group type: EXPERIMENTAL
Intervention: DMF 240 mg BID
Number of subjects: 341
Study 28751099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 26632295 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia simulation model (experimental group, N=30)
Number of subjects: 60
Study 26632295 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia administered by students who practiced on the simulation model (experimental group, N=30)
Number of subjects: 60
Study 26632295 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=30)
Number of subjects: 60
Study 23945891 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (25 mg/kg/day) started in the first 48 hours after admission
Number of subjects: 57
Study 23945891 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (25 mg/kg/day) administered after the first 48 hours
Number of subjects: 57
Study 20864468 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Style (WS) intervention
Number of subjects: 466
Study 20864468 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Style plus Physical Activity (WSPA) intervention
Number of subjects: 466
Study 20864468 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 466
Study 19084098 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 162
Study 19084098 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 162
Study 19084098 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 162
Study 16781228 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 16781228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive contemporary management
Number of subjects: 0
Study 16781228 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition started early post-coronary artery bypass graft
Number of subjects: 0
Study 11773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise training (EX)
Number of subjects: 100
Study 11773209 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education program (NU)
Number of subjects: 100
Study 11773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EX and NU)
Number of subjects: 100
Study 10359339 — intervention group
Group type: EXPERIMENTAL
Intervention: Grating acuity assessment
Number of subjects: 73
Study 10359339 — intervention group
Group type: EXPERIMENTAL
Intervention: HOTV letter acuity assessment
Number of subjects: 73
Study 10359339 — intervention group
Group type: EXPERIMENTAL
Intervention: ETDRS letter acuity assessment
Number of subjects: 73
Study 10359339 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall interobserver agreement
Number of subjects: 73
Study 7491394 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 8
Study 7491394 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8
Study 7491394 — intervention group
Group type: COMPARATOR
Intervention: Live ratings
Number of subjects: 8
Study 7491394 — intervention group
Group type: COMPARATOR
Intervention: Videotape ratings
Number of subjects: 8
Study 2387675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation
Number of subjects: 113
Study 2387675 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 113
Study 2387675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 2387675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine and Riboflavin supplementation in subjects with initially deficient biochemical vitamin status
Number of subjects: 113
Study 7264274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine (DEC)
Number of subjects: 0
Study 7264274 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 0
Study 7264274 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diethylcarbamazine (DEC)
Number of subjects: 0
Study 7264274 — intervention group
Group type: COMPARATOR
Intervention: Levamisole
Number of subjects: 0
Study 7264274 — intervention group
Group type: COMPARATOR
Intervention: Yeast tablets
Number of subjects: 0
Study 29536140 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT and VTT
Number of subjects: 48
Study 29536140 — intervention group
Group type: COMPARATOR
Intervention: PFMT
Number of subjects: 48
Study 28685204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (loading dose 20 mg, maintenance dose 3.75 mg/day for 7 days)
Number of subjects: 45
Study 28685204 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (maintenance dose 3.75 mg/day for 7 days)
Number of subjects: 45
Study 28685204 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day after switching from prasugrel)
Number of subjects: 45
Study 25537736 — intervention group
Group type: EXPERIMENTAL
Intervention: air-Q
Number of subjects: 96
Study 25537736 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 96
Study 25455003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg bid
Number of subjects: 135
Study 25455003 — intervention group
Group type: COMPARATOR
Intervention: Placebo bid
Number of subjects: 135
Study 22520621 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol-rich grape supplement (resveratrol 8 mg)
Number of subjects: 75
Study 22520621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 75
Study 22520621 — intervention group
Group type: COMPARATOR
Intervention: Conventional grape supplement lacking resveratrol
Number of subjects: 75
Study 19525871 — intervention group
Group type: EXPERIMENTAL
Intervention: L reuteri (1 x 10 CFU)
Number of subjects: 232
Study 19525871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 17544870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg/day for 12 weeks)
Number of subjects: 48
Study 17544870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 17544870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 48
Study 15338850 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone plus pacing
Number of subjects: 160
Study 15338850 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 160
Study 15338850 — intervention group
Group type: COMPARATOR
Intervention: Pacing
Number of subjects: 160
Study 15338850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11438377 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg daily for 6 months)
Number of subjects: 38
Study 11438377 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (3.75 mg every 28 days for 6 months)
Number of subjects: 38
Study 11438377 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 38
Study 11438377 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment (3 months after termination of both treatments)
Number of subjects: 38
Study 9053474 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage treatments after MOPP-ABVD
Number of subjects: 115
Study 9053474 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chemotherapy re-treatment
Number of subjects: 115
Study 9053474 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy or new regimens
Number of subjects: 115
Study 8429117 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily (bid)
Number of subjects: 12
Study 8429117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg bid
Number of subjects: 12
Study 8429117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 300 mg bid
Number of subjects: 12
Study 8429117 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 12
Study 3619738 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% forskolin (colforsin)
Number of subjects: 15
Study 3619738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated eye)
Number of subjects: 15
Study 3619738 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin (treated eye)
Number of subjects: 15
Study 3619738 — intervention group
Group type: COMPARATOR
Intervention: Timolol pretreatment (placebo-treated eye)
Number of subjects: 15
Study 3619738 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol pretreatment (forskolin-treated eye)
Number of subjects: 15
Study 30783676 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (live-attenuated tetravalent dengue vaccine candidate)
Number of subjects: 0
Study 30807638 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eyes of patients with unilateral RVO
Number of subjects: 83
Study 27649463 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual surgical planning (VSP)
Number of subjects: 16
Study 27649463 — intervention group
Group type: COMPARATOR
Intervention: Traditional planning
Number of subjects: 16
Study 25765588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-zone programming group (VT1: 171-200 bpm, VT2: 200-230 bpm, VF: >230 bpm)
Number of subjects: 223
Study 25765588 — intervention group
Group type: EXPERIMENTAL
Intervention: High-zone programming group
Number of subjects: 223
Study 25765588 — intervention group
Group type: COMPARATOR
Intervention: Conventional programming group (VT1: 167-182 bpm, VT2: 182-200 bpm, VF: >200 bpm)
Number of subjects: 223
Study 25765588 — intervention group
Group type: COMPARATOR
Intervention: Conventional programming group
Number of subjects: 223
Study 23819241 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking with vaccaria seeds applied at Shenmen (TF 4), Wei (CO 4), and Jiaogan (AH 6a) before the operation and at 1, 5, 9, 23 hours after the operation, pressed for 5 minutes each point each time.
Number of subjects: 120
Study 23819241 — intervention group
Group type: COMPARATOR
Intervention: Placebo group with the same point selection and sticking paste but no sticking or pressing with vaccaria seeds.
Number of subjects: 120
Study 21289258 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg denosumab every 6 months for 24 months
Number of subjects: 256
Study 21289258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 21289258 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (after discontinuation)
Number of subjects: 256
Study 21289258 — intervention group
Group type: COMPARATOR
Intervention: Denosumab and Placebo (off-treatment phase)
Number of subjects: 256
Study 19814758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivation interview by a trained interventionist and an injury prevention brochure (Intervention Group - IG)
Number of subjects: 292
Study 19814758 — intervention group
Group type: COMPARATOR
Intervention: Injury prevention brochure only (Control Group - CG)
Number of subjects: 292
Study 16632297 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zinc sulfate treatment
Number of subjects: 0
Study 16632297 — intervention group
Group type: COMPARATOR
Intervention: Starch as placebo
Number of subjects: 0
Study 14754691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg synthetic conjugated estrogens
Number of subjects: 281
Study 14754691 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg synthetic conjugated estrogens
Number of subjects: 281
Study 14754691 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg synthetic conjugated estrogens
Number of subjects: 281
Study 14754691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 10910019 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective adsorption (SA) followed by intravenous immunoglobulin (i.v. IgG)
Number of subjects: 45
Study 10910019 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (PE)
Number of subjects: 45
Study 10910019 — intervention group
Group type: COMPARATOR
Intervention: Selective adsorption (SA) using a tryptophan-linked polyvinyl alcohol gel adsorbent
Number of subjects: 45
Study 9062837 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal three meals per day containing usual energy intake
Number of subjects: 4
Study 9062837 — intervention group
Group type: EXPERIMENTAL
Intervention: One meal per day (dinner time) containing 50% of usual energy intake
Number of subjects: 4
Study 9062837 — intervention group
Group type: EXPERIMENTAL
Intervention: Three meals per day containing 50% of usual energy intake
Number of subjects: 4
Study 8112969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pefloxacin 400 mg
Number of subjects: 20
Study 3511312 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 6
Study 3511312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 6
Study 3511312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2456122 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatotomy (TUT)
Number of subjects: 49
Study 2456122 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatectomy (TUR)
Number of subjects: 49
Study 30928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CAF [cyclophosphamide, doxorubicin, 5‐fluorouracil] vs. CMF [cyclophosphamide, methotrexate, 5‐fluorouracil])
Number of subjects: 0
Study 30928413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (subgroup analysis)
Number of subjects: 0
Study 30928413 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 28428093 — intervention group
Group type: EXPERIMENTAL
Intervention: tONS at 2 Hz
Number of subjects: 110
Study 28428093 — intervention group
Group type: EXPERIMENTAL
Intervention: tONS at 100 Hz
Number of subjects: 110
Study 28428093 — intervention group
Group type: EXPERIMENTAL
Intervention: tONS at 2/100 Hz
Number of subjects: 110
Study 28428093 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate orally
Number of subjects: 110
Study 28428093 — intervention group
Group type: COMPARATOR
Intervention: Sham tONS
Number of subjects: 110
Study 25776729 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine transdermal patch (test formulation)
Number of subjects: 0
Study 25776729 — intervention group
Group type: COMPARATOR
Intervention: Clonidine transdermal patch (reference formulation)
Number of subjects: 0
Study 23195993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel refinery workers
Number of subjects: 18
Study 23195993 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 18
Study 21646329 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subdural motor cortex stimulation
Number of subjects: 11
Study 19114687 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (cumulative dose, 50 Gy)
Number of subjects: 264
Study 19114687 — intervention group
Group type: COMPARATOR
Intervention: Control (no radiotherapy)
Number of subjects: 264
Study 19114687 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 264
Study 19114687 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 264
Study 16988209 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg)
Number of subjects: 0
Study 16988209 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (60 mg)
Number of subjects: 0
Study 16988209 — intervention group
Group type: COMPARATOR
Intervention: S18982 (active metabolite)
Number of subjects: 0
Study 15080820 — intervention group
Group type: EXPERIMENTAL
Intervention: Butterbur (BB) 50 mg twice daily
Number of subjects: 16
Study 15080820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (FEX) 180 mg once daily
Number of subjects: 16
Study 15080820 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 10835090 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (betamethasone)
Number of subjects: 0
Study 10835090 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0